Therapeutics

Latest issue out now. Keep up to date on the most recent regulatory changes in the world of pharma, biotech and medical device clinical trials with ICON’s Regulatory Intelligence Newsletter. Join thousands of subscribe...

Attending #ADPD2026 on 17-21 March? Visit us at booth #29 to learn how ICON is accelerating CNS trials and helping to drive collaboration across advocacy groups, biotech, pharma, and regulators. https://ow.ly/Abvc50Y8Fa0

The type of immunosuppressive treatment a patient with a rare autoimmune condition receives may impact how they respond to vaccines. Read our new article to explore this and other factors that can help determine the best...

A multi phase ICON supported study details the leading symptoms in advanced/metastatic HCC including fatigue, weight loss, weakness, appetite loss, and sleep disturbance. Findings show wide ranging effects on daily fun...

The oncology R&D landscape is rapidly evolving, driven by multi‑modality therapeutics, precision‑designed studies, and the growing measurable impact of AI on discovery and development. These shifts are reshaping how spon...

Vaccine guidance for patients with rare autoimmune diseases can be challenging, given the low prevalence of some of these conditions and limited understanding of the impacts of vaccines in these patients. Discover how va...

Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. This article in SelectScience® Science explores the evolving NIT landscape, emerging...

On 15 April at 12:00 pm, join ICON’s Alan Baldridge at the GLP‑1‑Based Therapeutics Summit for his session, “Is there anything GLP‑1s can’t do? Unlocking the next generation of metabolic treatments.” He will offer a fo...

Recent findings highlight the continued relevance and reliability of the Oswestry Disability Index instrument for evaluating disability in patients with Degenerative Disc Disease. Study participants demonstrated strong...

Ahead of World Obesity Day tomorrow, explore how ICON successfully supported a sponsors cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate ...

The FDA recent draft guidance sets out how Bayesian statistical methods can be applied across drug and biologics development. While Bayesian approaches have been used in medical devices and rare diseases, this is the f...

Approximately 5% of the world’s population is affected by a Rare Disease. ICON is committed to raising awareness and generating change for people worldwide living with Rare Diseases, their families and carers. Learn ho...